<p>阿卡迪亚制药（NASDAQ:ACAD - 获取免费报告）在周四发布的研究报告中，皇家银行的研究分析师将其目标价从 34.00 美元下调至 32.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “跑赢大盘” 的评级。皇家银行的目标价暗示该公司股价有 49.95% 的潜在上涨空间。</p>
<ul>
<li>阿卡迪亚制药：一家正在大幅波动的中型生物科技公司</li>
</ul>
<p>其他一些研究分析师最近也对阿卡迪亚制药发表了评论。华尔街 Zen 在 9 月 5 日的研究报告中将阿卡迪亚制药的评级从 “买入” 下调至 “持有”。瑞银集团在 9 月 9 日的研究报告中将阿卡迪亚制药的目标价从 36.00 美元上调至 39.00 美元，并给予该股票 “买入” 评级。高盛集团在 8 月 7 日的研究报告中将阿卡迪亚制药的目标价从 15.00 美元上调至 17.00 美元，并给予该公司 “卖出” 评级。Needham &amp; Company LLC 在周四的报告中将阿卡迪亚制药的目标价从 28.00 美元上调至 29.00 美元，并给予该股票 “买入” 评级。最后，摩根大通在 9 月 29 日的报告中将阿卡迪亚制药的目标价从 34.00 美元下调至 33.00 美元，并对该股票设定了 “增持” 评级。一位分析师给予该股票 “强烈买入” 评级，十二位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，阿卡迪亚制药目前的平均评级为 “适度买入”，共识目标价为 28.94 美元。</p>
<p>获取 <strong>阿卡迪亚制药</strong> 的提醒：</p>
<p><strong>获取我们对阿卡迪亚制药的最新股票分析</strong></p>
<h2>阿卡迪亚制药股票表现</h2>
<p>周四，阿卡迪亚制药（NASDAQ:ACAD）的股票在交易时段下跌 0.99 美元，报 21.34 美元。该公司 385,179 股股票成交，低于其平均成交量 2,152,248 股。该公司的 50 日简单移动平均线为 22.78 美元，200 日简单移动平均线为 21.84 美元。该公司的市值为 36 亿美元，市盈率为 16.05，市盈增长比率为 7.90，贝塔值为 0.80。阿卡迪亚制药的 52 周最低价为 13.40 美元，52 周最高价为 26.65 美元。</p>
<p>阿卡迪亚制药（NASDAQ:ACAD - 获取免费报告）最近在 11 月 5 日发布了季度财报。这家生物制药公司报告每股收益为 0.42 美元，超出分析师共识预期的 0.14 美元，超出幅度为 0.28 美元。该公司季度收入为 2.7863 亿美元，超过分析师预期的 2.7652 亿美元。阿卡迪亚制药的股本回报率为 14.69%，净利润率为 21.80%。阿卡迪亚制药的收入同比增长 11.3%。去年同期，该公司每股收益为 0.20 美元。阿卡迪亚制药已设定 2025 财年的每股收益指导。分析师预计阿卡迪亚制药在当前财年将发布 0.7 美元的每股收益。</p>
<h2>阿卡迪亚制药的内部活动</h2>
<p>在其他阿卡迪亚制药的新闻中，执行副总裁 Mark C. Schneyer 在 9 月 15 日的交易中出售了 3,498 股公司股票。股票以平均价格 23.65 美元出售，总交易额为 82,727.70 美元。出售完成后，该执行副总裁持有 43,447 股公司股票，价值约为 1,027,521.55 美元。此次交易使其持股减少了 7.45%。该交易已在 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，董事 Elizabeth A. Garofalo 在 9 月 2 日的交易中出售了 1,600 股股票。股票以平均价格 25.98 美元出售，总价值为 41,568.00 美元。交易完成后，该董事直接持有 25,382 股公司股票，价值 659,424.36 美元。此次交易使其持股减少了 5.93%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士共出售了 27,098 股公司股票，价值 678,256 美元。公司内部人士持有 26.50% 的股票。</p>
<h2>对阿卡迪亚制药的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Geneos Wealth Management Inc.在第三季度将其在阿卡迪亚制药的持仓增加了 113.0%。Geneos Wealth Management Inc.目前持有 1,425 股该生物制药公司的股票，价值 30,000 美元，此前在该期间内又购买了 756 股。Banque Transatlantique SA 在第一季度获得了阿卡迪亚制药的新股份，价值约 31,000 美元。Picton Mahoney Asset Management 在第一季度获得了阿卡迪亚制药的新股份，价值约 32,000 美元。Smartleaf Asset Management LLC 在第三季度将其在阿卡迪亚制药的持仓增加了 107.0%。Smartleaf Asset Management LLC 目前持有 1,712 股该生物制药公司的股票，价值 36,000 美元，此前又购买了 885 股。最后，Federated Hermes Inc.在第一季度将其在阿卡迪亚制药的持仓增加了 231.5%。Federated Hermes Inc.目前持有 2,317 股该生物制药公司的股票，价值 38,000 美元，此前在上个季度又购买了 1,618 股。机构投资者和对冲基金持有该公司 96.71% 的股票。</p>
<h2>关于阿卡迪亚制药</h2>
<p>（获取免费报告）</p>
<p>阿卡迪亚制药公司是一家生物制药公司，专注于开发和商业化创新药物，以满足美国中枢神经系统（CNS）疾病和罕见疾病的未满足医疗需求。该公司提供 NUPLAZID（匹马伐森）用于治疗与帕金森病精神病相关的幻觉和妄想；以及 DAYBUE，这是一种合成的胰岛素样生长因子 1 氨基末端三肽的新型类似物，用于治疗雷特综合症。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过阿卡迪亚制药</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Dutch Bros 连续第 11 个季度超出收益预期</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>从股息到增长：为什么这三只股票在 2025 年脱颖而出</li>
<li>支撑和阻力的基础知识</li>
<li>AMD 的价格回调意味着机会：大幅收益即将到来</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在阿卡迪亚制药吗？</h2>
<p>在考虑阿卡迪亚制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿卡迪亚制药并不在名单上。</p>
<p>虽然阿卡迪亚制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿卡迪亚

<p>加拿大皇家银行已将阿卡迪亚制药的目标股价从 34.00 美元下调至 32.00 美元，同时维持 “跑赢大盘” 的评级。这表明与前一交易日收盘价相比，仍有 49.95% 的潜在上涨空间。其他分析师的观点各异，评级从强烈买入到卖出不等。阿卡迪亚的股票表现显示最近的交易价格为 21.34 美元，市值为 36 亿美元。该公司报告了上一季度每股收益为 0.42 美元，超出预期，并已将 2025 财年的指引设定为每股收益 0.7 美元</p>

<p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) had its price target dropped by research analysts at Royal Bank Of Canada from $34.00 to $32.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an &#34;outperform&#34; rating on the biopharmaceutical company's stock. Royal Bank Of Canada's target price would suggest a potential upside of 49.95% from the company's previous close.</p>
<div class="lb-trans"><p>阿卡迪亚制药（NASDAQ:ACAD - 获取免费报告）在周四发布的研究报告中，皇家银行的研究分析师将其目标价从 34.00 美元下调至 32.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “跑赢大盘” 的评级。皇家银行的目标价暗示该公司股价有 49.95% 的潜在上涨空间。</p>
</div><ul>
<li>Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves</li>
</ul>
<div class="lb-trans"><ul>
<li>阿卡迪亚制药：一家正在大幅波动的中型生物科技公司</li>
</ul>
</div><p>A number of other research analysts also recently commented on ACAD. Wall Street Zen downgraded ACADIA Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, September 5th. UBS Group upped their price target on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 9th. The Goldman Sachs Group raised their price objective on ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the company a &#34;sell&#34; rating in a research note on Thursday, August 7th. Needham &amp; Company LLC boosted their target price on ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Finally, JPMorgan Chase &amp; Co. lowered their price target on ACADIA Pharmaceuticals from $34.00 to $33.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, September 29th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $28.94.</p>
<div class="lb-trans"><p>其他一些研究分析师最近也对阿卡迪亚制药发表了评论。华尔街 Zen 在 9 月 5 日的研究报告中将阿卡迪亚制药的评级从 “买入” 下调至 “持有”。瑞银集团在 9 月 9 日的研究报告中将阿卡迪亚制药的目标价从 36.00 美元上调至 39.00 美元，并给予该股票 “买入” 评级。高盛集团在 8 月 7 日的研究报告中将阿卡迪亚制药的目标价从 15.00 美元上调至 17.00 美元，并给予该公司 “卖出” 评级。Needham &amp; Company LLC 在周四的报告中将阿卡迪亚制药的目标价从 28.00 美元上调至 29.00 美元，并给予该股票 “买入” 评级。最后，摩根大通在 9 月 29 日的报告中将阿卡迪亚制药的目标价从 34.00 美元下调至 33.00 美元，并对该股票设定了 “增持” 评级。一位分析师给予该股票 “强烈买入” 评级，十二位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，阿卡迪亚制药目前的平均评级为 “适度买入”，共识目标价为 28.94 美元。</p>
</div><p>Get <strong>ACADIA Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>阿卡迪亚制药</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Analysis on ACADIA Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对阿卡迪亚制药的最新股票分析</strong></p>
</div><h2>ACADIA Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>阿卡迪亚制药股票表现</h2>
</div><p>Shares of NASDAQ:ACAD traded down $0.99 during trading hours on Thursday, hitting $21.34. 385,179 shares of the company's stock traded hands, compared to its average volume of 2,152,248. The company's fifty day simple moving average is $22.78 and its two-hundred day simple moving average is $21.84. The company has a market cap of $3.60 billion, a price-to-earnings ratio of 16.05, a price-to-earnings-growth ratio of 7.90 and a beta of 0.80. ACADIA Pharmaceuticals has a 52 week low of $13.40 and a 52 week high of $26.65.</p>
<div class="lb-trans"><p>周四，阿卡迪亚制药（NASDAQ:ACAD）的股票在交易时段下跌 0.99 美元，报 21.34 美元。该公司 385,179 股股票成交，低于其平均成交量 2,152,248 股。该公司的 50 日简单移动平均线为 22.78 美元，200 日简单移动平均线为 21.84 美元。该公司的市值为 36 亿美元，市盈率为 16.05，市盈增长比率为 7.90，贝塔值为 0.80。阿卡迪亚制药的 52 周最低价为 13.40 美元，52 周最高价为 26.65 美元。</p>
</div><p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.28. The firm had revenue of $278.63 million for the quarter, compared to analysts' expectations of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.ACADIA Pharmaceuticals's revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the business posted $0.20 EPS. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that ACADIA Pharmaceuticals will post 0.7 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿卡迪亚制药（NASDAQ:ACAD - 获取免费报告）最近在 11 月 5 日发布了季度财报。这家生物制药公司报告每股收益为 0.42 美元，超出分析师共识预期的 0.14 美元，超出幅度为 0.28 美元。该公司季度收入为 2.7863 亿美元，超过分析师预期的 2.7652 亿美元。阿卡迪亚制药的股本回报率为 14.69%，净利润率为 21.80%。阿卡迪亚制药的收入同比增长 11.3%。去年同期，该公司每股收益为 0.20 美元。阿卡迪亚制药已设定 2025 财年的每股收益指导。分析师预计阿卡迪亚制药在当前财年将发布 0.7 美元的每股收益。</p>
</div><h2>Insider Activity at ACADIA Pharmaceuticals</h2>
<div class="lb-trans"><h2>阿卡迪亚制药的内部活动</h2>
</div><p>In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $23.65, for a total transaction of $82,727.70. Following the completion of the sale, the executive vice president owned 43,447 shares in the company, valued at approximately $1,027,521.55. The trade was a 7.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total value of $41,568.00. Following the completion of the transaction, the director directly owned 25,382 shares in the company, valued at $659,424.36. The trade was a 5.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 27,098 shares of company stock valued at $678,256. 26.50% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他阿卡迪亚制药的新闻中，执行副总裁 Mark C. Schneyer 在 9 月 15 日的交易中出售了 3,498 股公司股票。股票以平均价格 23.65 美元出售，总交易额为 82,727.70 美元。出售完成后，该执行副总裁持有 43,447 股公司股票，价值约为 1,027,521.55 美元。此次交易使其持股减少了 7.45%。该交易已在 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，董事 Elizabeth A. Garofalo 在 9 月 2 日的交易中出售了 1,600 股股票。股票以平均价格 25.98 美元出售，总价值为 41,568.00 美元。交易完成后，该董事直接持有 25,382 股公司股票，价值 659,424.36 美元。此次交易使其持股减少了 5.93%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士共出售了 27,098 股公司股票，价值 678,256 美元。公司内部人士持有 26.50% 的股票。</p>
</div><h2>Hedge Funds Weigh In On ACADIA Pharmaceuticals</h2>
<div class="lb-trans"><h2>对阿卡迪亚制药的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 756 shares during the period. Banque Transatlantique SA acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $31,000. Picton Mahoney Asset Management bought a new stake in shares of ACADIA Pharmaceuticals in the first quarter valued at about $32,000. Smartleaf Asset Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 107.0% during the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 885 shares during the period. Finally, Federated Hermes Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 1,618 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Geneos Wealth Management Inc.在第三季度将其在阿卡迪亚制药的持仓增加了 113.0%。Geneos Wealth Management Inc.目前持有 1,425 股该生物制药公司的股票，价值 30,000 美元，此前在该期间内又购买了 756 股。Banque Transatlantique SA 在第一季度获得了阿卡迪亚制药的新股份，价值约 31,000 美元。Picton Mahoney Asset Management 在第一季度获得了阿卡迪亚制药的新股份，价值约 32,000 美元。Smartleaf Asset Management LLC 在第三季度将其在阿卡迪亚制药的持仓增加了 107.0%。Smartleaf Asset Management LLC 目前持有 1,712 股该生物制药公司的股票，价值 36,000 美元，此前又购买了 885 股。最后，Federated Hermes Inc.在第一季度将其在阿卡迪亚制药的持仓增加了 231.5%。Federated Hermes Inc.目前持有 2,317 股该生物制药公司的股票，价值 38,000 美元，此前在上个季度又购买了 1,618 股。机构投资者和对冲基金持有该公司 96.71% 的股票。</p>
</div><h2>About ACADIA Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于阿卡迪亚制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.</p>
<div class="lb-trans"><p>阿卡迪亚制药公司是一家生物制药公司，专注于开发和商业化创新药物，以满足美国中枢神经系统（CNS）疾病和罕见疾病的未满足医疗需求。该公司提供 NUPLAZID（匹马伐森）用于治疗与帕金森病精神病相关的幻觉和妄想；以及 DAYBUE，这是一种合成的胰岛素样生长因子 1 氨基末端三肽的新型类似物，用于治疗雷特综合症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than ACADIA Pharmaceuticals</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Dutch Bros Beats Earnings for 11th Consecutive Quarter</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
<li>The Basics of Support and Resistance</li>
<li>AMD’s Price Pullback Equals Opportunity: The Big Gains Are Coming</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过阿卡迪亚制药</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Dutch Bros 连续第 11 个季度超出收益预期</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>从股息到增长：为什么这三只股票在 2025 年脱颖而出</li>
<li>支撑和阻力的基础知识</li>
<li>AMD 的价格回调意味着机会：大幅收益即将到来</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ACAD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在阿卡迪亚制药吗？</h2>
</div><p>Before you consider ACADIA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿卡迪亚制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿卡迪亚制药并不在名单上。</p>
</div><p>While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿卡迪亚制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

加拿大皇家银行的分析师将阿卡迪亚制药（NASDAQ:ACAD）的目标股价下调至 32.00 美元